Gujarat Themis Biosyn Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Gujarat Themis Biosyn Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 0 % on December 2025 . This represents a CAGR of -100.00% over 9 yearsThe Dividend Payout of Sanofi India Ltd changed from 119.34 % on December 2021 to 86.59 % on December 2025 . This represents a CAGR of -6.21% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Sanofi India Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,063 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Sanofi India Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Sanofi India Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹372.95. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.